luspatercept

💊Medication

Generic name

Luspatercept

Brand names

Reblozyl

Drug class

Erythroid Maturation Agent, Other antianemic preparations

Active ingredients

luspatercept

Route

Subcutaneous

Dosage form

Injection

Type

Human Prescription Drug

Manufacturer

Celgene Corporation

Indications: 1 INDICATIONS AND USAGE REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions ( 1.1 ). • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult pat… (per FDA label)

• PHASE2ACTIVE_NOT_RECRUITING
  Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN NeoplasmsH. Lee Moffitt Cancer Center and Research Institute · NCT05732961
• PHASE3COMPLETED
  A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesCelgene · NCT02631070
• PHASE2NOT_YET_RECRUITING
  The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCTInstitute of Hematology & Blood Diseases Hospital, China · NCT07450313
• PHASE1/PHASE2SUSPENDED
  Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS PatientsMikkael Sekeres, MD · NCT04539236
• ACTIVE_NOT_RECRUITING
  A Study to Evaluate Treatment Patterns and Effectiveness of LuspaterceptBristol-Myers Squibb · NCT06971185
• PHASE3ACTIVE_NOT_RECRUITING
  An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsCelgene · NCT04717414

via ClinicalTrials.gov